Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels

Two separate expert panels were convened to develop recommendations for side effect management with iDRS and optimizing iDRS insertion procedure success. Stepwise treatment-specific management strategies for LUTS, UTIs, and hematuria in patients receiving iDRS treatment that are familiar to practicing urologists are presented, including considerations for continuation or discontinuation of iDRS treatment. Several advanced techniques can be considered to improve iDRS insertions based on variations in patient anatomy.

Authors

Institutions

Publication Details

Journal
Current Opinion in Urology
Published
2025-10-07
DOI
https://doi.org/10.1097/mou.0000000000001350
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels

Spyros Triantos, Christopher Pieczonka, Bernardo Herrera‐Imbroda, Maarten Schuit et al.
Current Opinion in Urology
Bladder and Urothelial Cancer Treatments
article

Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels

Spyros Triantos, Christopher Pieczonka, Bernardo Herrera‐Imbroda, Maarten Schuit, John P.F.A. Heesakkers, Wolfgang Jessner, David Cahn, Benjamin Pradère, Sumeet Bhanvadia, John Maffeo, Félix Guerrero‐Ramos, Robert A. Somer, Yige Bao, Hussein Sweiti, Kenneth M. Peters, Shahrokh François Shariat, Joseph M Jacob, Bart De Troyer, David S. Morris, Sarah P. Psutka, Qiang Wei, Hiroshi Kitamura, Cristina Sánchez de Llano
article en

Abstract

Two separate expert panels were convened to develop recommendations for side effect management with iDRS and optimizing iDRS insertion procedure success. Stepwise treatment-specific management strategies for LUTS, UTIs, and hematuria in patients receiving iDRS treatment that are familiar to practicing urologists are presented, including considerations for continuation or discontinuation of iDRS treatment. Several advanced techniques can be considered to improve iDRS insertions based on variations in patient anatomy.

Current Opinion in UrologyVol. 36(1)
Al-Ahliyya Amman University (JO), Johnson & Johnson (United States) (US), Colorado Christian University (US), SUNY Upstate Medical University (US), Cornell University (US), Sichuan University (CN), Maastricht University (NL), Johnson & Johnson (Switzerland) (CH), Fred Hutch Cancer Center (US), West China Hospital of Sichuan University (CN), Comprehensive Cancer Center Vienna (AT), Urology Associates (US), Hospital Universitario 12 De Octubre (ES), Syracuse VA Medical Center (US), Vlaamse Vereniging voor Obstetrie en Gynaecolo (BE), Beaumont Hospital, Royal Oak (US), Colorado Center for Bone Research (US), Hospital Clínico Universitario Virgen de la Victoria (ES), Johnson & Johnson (Netherlands) (NL), Beaumont Hospital, Troy (US), University of Toyama (JP), Medical University of Vienna (AT), The University of Texas Southwestern Medical Center (US)
Openalex Percentile: Top 55%
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.